Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: An individual patient data meta-analysis

Preventive Veterinary Medicine

Volumn 112, Issue 3-4, 2013, Pages 414-422

  Schmidt, A F ^a,b,c   Nielen, M ^c   Klungel, O H ^a,b   Hoes, A W ^a   de Boer, A ^b   Groenwold, R H H ^a,b   Kirpensteijn, J ^d   Amsellem, Pierre ^e   Bacon, Nicholas ^f   Berg, John ^g   Kow, Kelvin ^f   Kurzman, Ilene ^h   Maritato, Karl ⁱ   Moore, Antony ^j   Morello, Emanuela ^k   Sottnik, Joe ^l   Vail, David ^h  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF PRINCE EDWARD ISLAND   (Canada)

^f University of Florida College of Veterinary Medicine   (United States)

^g TUFTS UNIVERSITY   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ MedVet Medical and Cancer Centers for Pets   (United States)

^j Veterinary Oncology Consultants ^*  (Australia)

^k School of Veterinary Medicine   (Italy)

^l Animal Cancer Center   (United States)

more..

Author keywords

Cancer; Canine; Disease free survival; Oncology; Risk factors; Survival

Indexed keywords

CANIS FAMILIARIS;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER;

AGE; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; BODY WEIGHT; BONE TUMOR; CANINE; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; FEMALE; GENETICS; MALE; META ANALYSIS; METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; ONCOLOGY; OSTEOSARCOMA; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; SURVIVAL;

CANCER; CANINE; DISEASE FREE SURVIVAL; ONCOLOGY; RISK FACTORS; SURVIVAL;

AGE FACTORS; ALKALINE PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BODY WEIGHT; BONE NEOPLASMS; DOG DISEASES; DOGS; FEMALE; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROPORTIONAL HAZARDS MODELS; SEX FACTORS;

EID: 84886788666     PISSN: 01675877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prevetmed.2013.08.011     Document Type: Article

References (34)

1. Bacon N.J., Ehrhart N.P., Dernell W.S., Lafferty M., Withrow S.J. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). J. Am. Vet. Med. Assoc. 2008, 232:1504-1510.
2. Berg J., Gebhardt M.C., Rand W.M. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997, 79:1343-1350.
3. Boerman I., Selvarajah G.T., Nielen M., Kirpensteijn J. Prognostic factors in canine appendicular osteosarcoma - a meta-analysis. BMC Vet. Res. 2012, 8:56.
4. Brodey R.S., Abt D.A. Results of surgical treatment in 65 dogs with osteosarcoma. J. Am. Vet. Med. Assoc. 1976, 168:1032-1035.
5. Cooley D.M., Waters D.J. Skeletal neoplasms of small dogs: a retrospective study and literature review. J. Am. Anim. Hosp. Assoc. 1997, 33:11-23.
6. Easterbrook P.J., Berlin J.A., Gopalan R., Matthews D.R. Publication bias in clinical research. Lancet 1991, 337:867-872.
7. Harrell F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis 2001, Springer, New York.
8. Harrell, F.E., Jr., 2012. Hmisc: Harrell Miscellaneous. R package.
9. Harrell F.E., Jr., 2012. rms: Regression Modeling Strategies, R package.
10. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996, 15:361-387.
11. Kirpensteijn J., Kik M., Rutteman G.R., Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet. Pathol. 2002, 39:240-246.
12. Kow K., Thamm D.H., Terry J., Grunerud K., Bailey S.M., Withrow S.J., Lana S.E. Impact of telomerase status on canine osteosarcoma patients. J. Vet. Intern. Med. 2008, 22:1366-1372.
13. Kurzman I.D., MacEwen E.G., Rosenthal R.C., Fox L.E., Keller E.T., Helfand S.C., Vail D.M., Dubielzig R.R., Madewell B.R., Rodriguez C.O. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin. Cancer Res. 1995, 1:1595-1601.
14. Lau B., Cole S.R., Gange S.J. Competing risk regression models for epidemiologic data. Am. J. Epidemiol. 2009, 170:244-256.
15. Marshall A., Altman D.G., Holder R.L., Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med. Res. Methodol. 2009, 9:57.
16. McNeill C.J., Overley B., Shofer F.S., Kent M.S., Clifford C.A., Samluk M., Haney S., Van Winkle T.J., Sorenmo K.U. Characterization of the biological behaviour of appendicular osteosarcoma in Rottweilers and a comparison with other breeds: a review of 258 dogs. Vet. Comp. Oncol. 2007, 5:90-98.
17. Moore A.S., Dernell W.S., Ogilvie G.K., Kristal O., Elmslie R., Kitchell B., Susaneck S., Rosenthal R., Klein M.K., Obradovich J., Legendre A., Haddad T., Hahn K., Powers B.E., Warren D. Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. J. Vet. Intern. Med. 2007, 21:783-790.
18. Morello E., Vasconi E., Martano M., Peirone B., Buracco P. Pasteurized tumoral autograft and adjuvant chemotherapy for the treatment of canine distal radial osteosarcoma: 13 cases. Vet. Surg. 2003, 32:539-544.
19. Norrdin R.W., Powers B.E., Torgersen J.L., Smith R.E., Withrow S.J. Characterization of osteosarcoma cells from two sibling large-breed dogs. Am. J. Vet. Res. 1989, 50:1971-1975.
20. Phillips B., Powers B.E., Dernell W.S., Straw R.C., Khanna C., Hogge G.S., Vail D.M. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J. Am. Anim. Hosp. Assoc. 2009, 45:33-38.
21. R Development Core Team, 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
22. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010, 340:c221.
23. Rowell J.L., McCarthy D.O., Alvarez C.E. Dog models of naturally occurring cancer. Trends Mol. Med. 2011, 17:380-388.
24. Ru G., Terracini B., Glickman L.T. Host related risk factors for canine osteosarcoma. Vet. J. 1998, 156:31-39.
25. Satagopan J.M., Ben-Porat L., Berwick M., Robson M., Kutler D., Auerbach A.D. A note on competing risks in survival data analysis. Br. J. Cancer 2004, 91:1229-1235.
26. Sottnik J.L., Rao S., Lafferty M.H., Thamm D.H., Morley P.S., Withrow S.J., Dow S.W. Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. J. Vet. Intern. Med. 2010, 24:1439-1444.
27. Spodnick G.J., Berg J., Rand W.M., Schelling S.H., Couto G., Harvey H.J., Henderson R.A., MacEwen G., Mauldin N., McCaw D.L. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J. Am. Vet. Med. Assoc. 1992, 200:995-999.
28. Sterne J.A., White I.R., Carlin J.B., Spratt M., Royston P., Kenward M.G., Wood A.M., Carpenter J.R. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009, 338:b2393.
29. Stewart L.A., Parmar M.K. Meta-analysis of the literature or of individual patient data: is there a difference?. Lancet 1993, 341:418-422.
30. Steyerberg E.W., Vickers A.J., Cook N.R., Gerds T., Gonen M., Obuchowski N., Pencina M.J., Kattan M.W. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010, 21:128-138.
31. Straw R.C., Withrow S.J., Richter S.L., Powers B.E., Klein M.K., Postorino N.C., LaRue S.M., Ogilvie G.K., Vail D.M., Morrison W.B. Amputation and cisplatin for treatment of canine osteosarcoma. J. Vet. Intern. Med. 1991, 5:205-210.
32. Therneau, T., 2012. A Package for Survival Analysis in S.
33. Vail D.M., Kurzman I.D., Glawe P.C., O'Brien M.G., Chun R., Garrett L.D., Obradovich J.E., Fred R.M., Khanna C., Colbern G.T., Working P.K. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 2002, 50:131-136.
34. Withrow S.J., Wilkins R.M. Cross talk from pets to people: translational osteosarcoma treatments. ILAR J. 2010, 51:208-213.